Pfizer reports FDA approval for wider use of Aromasin

10/6/2005 | Bloomberg Businessweek

The FDA has expanded approval of the breast cancer drug to include post-surgery therapy for patients with early breast cancer, Pfizer said. The tablets have been approved since 1999 for treating advanced breast cancer after standard chemotherapy, and a study showed women who switched to Aromasin after two to three years of tamoxifen were more likely to avoid a cancer recurrence than those who continued with tamoxifen.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN